{
    "clinical_study": {
        "@rank": "13482", 
        "brief_summary": {
            "textblock": "To determine the safety, immunogenicity, biological activity, ad pharmacokinetics of\n      sargramostim ( recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF ) human\n      granulocyte-macrophage colony-stimulating factor ( GM-CSF ), given by subcutaneous ( SC )\n      injection to patients with leukopenia in association with HIV infection."
        }, 
        "brief_title": "An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia", 
        "condition": [
            "HIV Infections", 
            "Cytopenias"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Leukopenia", 
                "Virus Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Serum antibody to HIV with or without evidence of HIV.\n\n          -  Antigenemia.\n\n          -  Anticipated survival of at least 6 months.\n\n          -  Allowed:\n\n          -  Kaposi's sarcoma.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Malignancy other than Kaposi's sarcoma.\n\n          -  Excessive diarrhea (more than 5 liquid or non-liquid stools per day).\n\n          -  Currently hospitalized or hospitalized within the last 4 weeks for the treatment of\n             opportunistic infection.\n\n          -  Primary hematologic or infectious disorders unrelated to AIDS virus infection.\n\n          -  Dementia or altered mental status that would prohibit the giving and understanding of\n             informed consent.\n\n        Patients with the following are excluded:\n\n          -  History of malignancy other than Kaposi's sarcoma.\n\n          -  Currently hospitalized or hospitalized within 4 weeks for the treatment of\n             opportunistic infection.\n\n        Prior Medication:\n\n        Excluded within 3 weeks of study entry:\n\n          -  Marrow suppressive medication.\n\n          -  Excluded within 4 weeks of study entry:\n\n          -  Any investigational drug.\n\n        Prior Treatment:\n\n        Excluded within 4 weeks of study entry:\n\n          -  Systemic cytotoxic chemotherapy.\n\n          -  Irradiation.\n\n        Risk Behavior:\n\n        Excluded within 3 months of study entry:\n\n          -  Regular, excessive users of alcohol, hallucinogens, or agents which are addicting."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002008", 
            "org_study_id": "067D", 
            "secondary_id": "106"
        }, 
        "intervention": {
            "intervention_name": "Sargramostim", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "Leukopenia", 
            "Drug Evaluation", 
            "Granulocyte-Macrophage Colony-Stimulating Factor"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "UCLA CARE Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Deaconess - West Campus"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002008"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sandoz Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 1989"
    }, 
    "geocoordinates": {
        "Beth Israel Deaconess - West Campus": "42.358 -71.06", 
        "UCLA CARE Ctr": "34.052 -118.244"
    }
}